Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | EVP, CHIEF SCIENTIFIC OFFICER | September 03, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date September 03, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,660 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Sale · Disposed 709 · Balance 61,660 F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. F2: This transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.
F2: This transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 4, 2026 20:27 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 709 | $3.04 | $2,153.37 |
DisclosureSEC source: 0001985604-26-000003 · wk-form4_1788553659.xml · nonDerivative · entry 1 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,660 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.0050 to $3.0372. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 28, 2026 Filed Jul 29, 2026 20:51 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 4,928 | $2.67 | $13,157.76 |
DisclosureSEC source: 0001650664-26-000076 · wk-form4_1785358259.xml · nonDerivative · entry 1 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,369 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on July 24, 2026. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:32 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 731 | $2.70 | $1,974.50 |
DisclosureSEC source: 0001650664-26-000055 · wk-form4_1780691552.xml · nonDerivative · entry 1 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,297 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.7010 to $2.7050. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 20:34 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 292,856 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001650664-26-000021 · wk-form4_1773693286.xml · derivative · entry 1 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 292,856 Underlying: Common Stock · 292,856 shares Expires 2036-03-11 F1 · derivative.exercise_date: This option was granted on March 12, 2026 and is scheduled to vest over four years in equal monthly installments beginning on April 12, 2026 through March 12, 2030. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:48 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 749 | $2.02 | $1,512.68 |
DisclosureSEC source: 0001650664-26-000006 · wk-form4_1772660918.xml · nonDerivative · entry 1 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,028 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.0041 to $2.0204. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:39 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 713 | $2.15 | $1,535.16 |
DisclosureSEC source: 0001650664-25-000163 · wk-form4_1764884348.xml · nonDerivative · entry 1 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,777 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 20:21 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 710 | $2.60 | $1,843.23 |
DisclosureSEC source: 0001650664-25-000143 · wk-form4_1757017284.xml · nonDerivative · entry 1 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,490 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: The amount of securities beneficially owned following the reported transaction includes 5,802 shares acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| July 31, 2025 Filed Aug 4, 2025 20:49 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 5,121 | $2.49 | $12,756.92 |
DisclosureSEC source: 0001650664-25-000113 · wk-form4_1754340586.xml · nonDerivative · entry 1 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,398 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on July 24, 2025. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 22:37 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 726 | $1.72 | $1,251.84 |
DisclosureSEC source: 0001650664-25-000091 · wk-form4_1749076666.xml · nonDerivative · entry 1 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,519 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.7239 to $1.7522. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 08, 2025 Filed Mar 27, 2025 20:33 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001650664-25-000034 · wk-form4_1743107610.xml · derivative · entry 2 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2035-03-07 F2 · derivative.exercise_date: This option was granted on March 8, 2025 and is scheduled to vest in full on September 8, 2026. Read SEC document |
| March 08, 2025 Filed Mar 27, 2025 20:33 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 275,100 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001650664-25-000034 · wk-form4_1743107610.xml · derivative · entry 1 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,100 Underlying: Common Stock · 275,100 shares Expires 2035-03-07 F1 · derivative.exercise_date: This option was granted on March 8, 2025 and is scheduled to vest over four years in equal monthly installments beginning on April 8, 2025 through March 8, 2029. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:41 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 2,891 | $1.71 | $4,945.63 |
DisclosureSEC source: 0001650664-25-000025 · wk-form4_1741210903.xml · nonDerivative · entry 1 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,245 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 21:02 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 11,886 | $5.42 | $64,369.82 |
DisclosureSEC source: 0001650664-24-000090 · wk-form4_1722027729.xml · nonDerivative · entry 1 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,136 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on July 24, 2024. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 02, 2024 Filed Mar 6, 2024 01:03 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 74,400 | $0.00 Strike: $10.53 | $0.00 |
DisclosureSEC source: 0001650664-24-000017 · wk-form4_1709686999.xml · derivative · entry 3 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,400 Underlying: Common Stock · 74,400 shares Expires 2034-03-01 F3 · derivative.exercise_date: This option was granted on March 2, 2024 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2024 through March 2, 2028. Read SEC document |
| March 02, 2024 Filed Mar 6, 2024 01:03 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 15,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001650664-24-000017 · wk-form4_1709686999.xml · nonDerivative · entry 2 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,022 F2 · kind: Reflects the acquisition, upon the achievement of a specified business development milestone, of a portion of a performance-based restricted stock unit award originally granted on July 24, 2023. The shares subject to the restricted stock unit award remain subject to time-based vesting conditions and will vest on July 24, 2024, subject to continued service. Read SEC document |
| March 02, 2024 Filed Mar 6, 2024 01:03 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 24,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001650664-24-000017 · wk-form4_1709686999.xml · nonDerivative · entry 1 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,967 F1 · kind: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2025 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2028. Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 20:45 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 135,500 | $0.00 Strike: $8.66 | $0.00 |
DisclosureSEC source: 0001415889-23-011455 · form4-07252023_040701.xml · derivative · entry 2 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,500 Underlying: Common Stock · 135,500 shares Expires 2033-07-23 F2 · derivative.exercise_date: This option was granted on July 24, 2023 and is scheduled to vest over four years, with 25% of the shares to vest on July 24, 2024 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 24, 2027. Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 20:45 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 45,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-011455 · form4-07252023_040701.xml · nonDerivative · entry 1 Burkly Linda · CIK 0001985604 · EVP, CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,167 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on July 24, 2024 continuing through July 24, 2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.